Mizuho Maintains Buy on ResMed, Lowers Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone maintains a 'Buy' rating on ResMed (NYSE:RMD) but lowers the price target from $255 to $180.
September 13, 2023 | 2:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Mizuho maintains a 'Buy' rating on ResMed but lowers the price target from $255 to $180.
While Mizuho maintains a 'Buy' rating on ResMed, the lowering of the price target from $255 to $180 could create some uncertainty among investors. This might lead to short-term volatility in the stock price, but the overall impact is neutral as the 'Buy' rating is still maintained.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100